Volume 28, Number 12—December 2022
CME ACTIVITY - Research
Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China
Table 2
Multivariate analysis of risk factors for Acinetobacter baumannii among patients during invasive mechanical ventilation, China*
Variables | p value | Hazard ratio (95% CI) |
---|---|---|
Underlying conditions | ||
Cardiovascular diseases | 0.054 | 1.394 (0.994–1.955) |
Chronic renal insufficiency | 0.730 | 0.937 (0.648–1.356) |
COPD and asthma | 0.132 | 1.299 (0.924–1.825) |
Type 2 diabetes mellitus | 0.325 | 1.197 (0.837–1.714) |
Current or former smoker |
0.098 |
1.307 (0.951–1.797) |
Treatment | ||
No aerosol inhalation | Referent | |
Glucocorticoid aerosol inhalation | 0.038 | 1.528 (1.024–2.278) |
Aerosol inhalation without glucocorticoid | 0.524 | 0.829 (0.467–1.475) |
Broad-spectrum antimicrobial drugs, >7 d | 0.001 | 7.238 (2.758–15.788) |
Invasive mechanical ventilation, >5 d | 0.001 | 2.381 (1.664–3.405) |
Vasopressor treatment, >3 d | <0.001 | 2.060 (1.402–3.028) |
Renal dialysis, >3 d |
0.841 |
1.046 (0.675–1.620) |
APACHE II score | 0.586 | 0.992 (0.965–1.020) |
*Results are from model 2; only variables with p<0.1 in univariate analysis were included. APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease.
1These authors contributed equally to this article.